Related Experiment Video
Updated: Apr 7, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Implementing drug data exclusivity in China: a comparative analysis with global practices
1Center for Drug Evaluation, National Medical Products Administration, China.
Drug Discovery Today
|April 5, 2026
Summary
China is implementing a new drug data exclusivity system, balancing global intellectual property standards with domestic needs. This system aims to protect innovation while considering generic drug accessibility and AI-generated data challenges.
Area of Science:
- Pharmaceutical Policy
- Intellectual Property Law
- Health Economics
Background:
- China is establishing a drug data exclusivity system, aligning with global pharmaceutical intellectual property standards.
- Existing data exclusivity frameworks in the US, Canada, EU, and Japan provide context for China's upcoming policies.
- Understanding these systems is crucial for pharmaceutical innovation and market access.
Purpose of the Study:
- To provide a comprehensive overview and comparative analysis of China's drug data exclusivity system.
- To evaluate China's proposed framework against international intellectual property norms, specifically the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- To identify potential challenges and implications of China's system for stakeholders.
Main Methods:
- Comparative analysis of international data exclusivity systems (US, Canada, EU, Japan).
- Detailed examination of China's forthcoming policies, including exclusivity periods, protection mechanisms, and objectives.
- Evaluation of China's framework against TRIPS standards regarding scope and methods of protection.
Main Results:
- China's system shows alignment with TRIPS in protection scope and methods.
- Key aspects of China's system include defined exclusivity periods, specific protection mechanisms, and clear protection objectives.
- Potential challenges identified include impacts on generic drug accessibility, protection of AI-generated data, and policy overlap risks.
Conclusions:
- China's drug data exclusivity regime represents a strategic balance between international intellectual property norms and domestic industrial realities.
- The system's success will depend on effectively navigating challenges related to generic competition and evolving data generation technologies.
- Further analysis is needed to fully understand the long-term implications for pharmaceutical innovation and patient access in China.
Keywords:
Data exclusivityData protectionData protection regimeData protection systemDrug data exclusivityDrug data protectionExclusivityMarket exclusivityMore Related Videos
05:59An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
Published on: November 4, 2022
2.2K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.0K
Related Concept Videos
01:16Bioequivalence Data: Statistical Interpretation
333
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
333
01:13Bioequivalence studies: Biowaivers
398
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
398
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
01:17Drug Nomenclature
3.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.7K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
353
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
353
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72